Cargando…

Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS

OBJECTIVE: To assess the safety of ocrelizumab (OCR) shorter duration infusion in patients with MS. METHODS: ENSEMBLE PLUS is a randomized, double-blind substudy to the single-arm ENSEMBLE study (NCT03085810). In ENSEMBLE, patients with early stage relapsing-remitting MS received OCR 600 mg initiall...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hartung, Hans-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286651/ https://www.ncbi.nlm.nih.gov/pubmed/32503093 http://dx.doi.org/10.1212/NXI.0000000000000807

Ejemplares similares

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
por: Hartung, H-P, et al.
Publicado: (2020)

Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial
por: Bermel, Robert A., et al.
Publicado: (2021)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS)
por: Kister, Ilya, et al.
Publicado: (2023)

Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion
por: Cicero, Steven, et al.
Publicado: (2021)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions
por: Alvarez, Enrique, et al.
Publicado: (2022)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
por: Novi, Giovanni, et al.
Publicado: (2020)

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

Ocrelizumab-Induced Severe Colitis
por: Lee, Hsing Hwa, et al.
Publicado: (2020)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study
por: Smoot, Kyle, et al.
Publicado: (2021)

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO
por: Stringer, Beverley, et al.
Publicado: (2021)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS
por: Fuss, Carmina Teresa, et al.
Publicado: (2020)

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a
por: MacMillan, Erin L, et al.
Publicado: (2019)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study
por: Freedman, Mark S, et al.
Publicado: (2017)

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
por: Thornton, Jeanine Rempe, et al.
Publicado: (2020)

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study
por: Weber, Martin S., et al.
Publicado: (2022)

Shorter mothers have shorter pregnancies
por: Derraik, José, et al.
Publicado: (2015)

Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis
por: Dubbioso, Raffaele, et al.
Publicado: (2022)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ej2prmpg2lh7q2cqebrdpta4q1